+3.03% for Tilray stock as Montauk Brewing anniversary shows brand resilience

Traders Union
All News
Financial News
Tilray climbs 3.03% today to $4.60

Highlights

Tilray Medical's expanded UK cannabis access for veterans via Lyphe Clinic establishes a vertically integrated foothold post-acquisition, widening future revenue channels.
Montauk Brewing Co., Tilray's subsidiary, enters its 14th year, underscoring brand maturation and ongoing growth within the group's portfolio.
TLRY is consolidating between $4.41 and $4.79 amid mixed momentum signals, with a slightly higher probability of price decline near-term.

UK expansion and subsidiary growth as platform integration drives reach

Tilray Medical’s rollout of expanded medical cannabis access for veterans through the Lyphe Clinic at Aldershot’s Armed Forces Weekend marks a strategic milestone in the UK, following its acquisition of Lyphe Group and subsequent creation of a vertically integrated medical platform. This development broadens Tilray’s reach into the UK’s regulated market, potentially boosting patient numbers and future revenue streams. Additionally, Montauk Brewing Co., a subsidiary of Tilray Brands, is marking its 14th year of operations, according to The Globe and Mail, highlighting ongoing subsidiary maturation and brand recognition.

Mixed technical signals as bullish momentum faces indicator divergences

On the hourly chart, the price sits above the MA-20 at $4.56 but remains below the MA-50 at $4.67, and well under the MA-200 at $8.99, with immediate support at the Ichimoku Kijun level of $4.57. The Moving Average Convergence Divergence (MACD) signals a strong sell, the Average Directional Index (ADX) is neutral, while the Relative Strength Index (RSI) reads 54.8 and the Commodity Channel Index (CCI) is also giving a buy signal. The Stochastic RSI is in overbought territory, indicating the potential for near-term exhaustion, and Bull/Bear Power is on buy, reflecting intraday buyer dominance. The Awesome Oscillator is currently neutral, underlining the mixed momentum picture, with price action showing robust bullish energy intraday but the larger set of oscillators showing divergences.

Sideways price range expected as bearish risk edges higher

Over the coming trading sessions, TLRY is expected to consolidate in a range between $4.41 and $4.79, reflecting typical volatility relative to current levels. The probability tilts slightly in favor of a move lower, with 52% odds of decline compared to 48% for an advance. The baseline scenario is for continued sideways movement within this band, with a bullish extension possible if resistance is breached, and a bearish outcome if price slips below immediate support.

Anton Kharitonov, expert at Traders Union, sees Tilray’s recent UK medical expansion as a meaningful step, but believes technical signals present a conflicted outlook. The price shows intraday bullishness above key short-term averages, but momentum oscillators highlight risk of a move lower. He remains defensive given the 52% probability of decline and mixed indicators. "Until price clears $4.79 with strong volume, I remain cautious and see consolidation as the baseline scenario."

Earlier, analysts noted that Tilray’s ongoing international expansion was being overshadowed by persistent stock weakness and a dominant bearish tone. The current stabilization above key short-term moving averages and increased momentum from recent UK medical initiatives add a new dimension, making the $4.57 support level a crucial pivot for traders monitoring the next directional move.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.